Back to Authors

Myers, Robert P.

A5108739802 | I4210140816

Mayo Clinic

Gilead Sciences (United States)

Citations 52

Editorial Commentary

Urology Practice | April 23, 2014 | Volume: 1 | Issue: 2 | Pages: 90-91

10.1016/j.urpr.2014.03.007

The Whole Life Prostate Book: Everything that Every Man—at Every Age—Needs to Know About Maintaining Optimal Prostate HealthCarterH.B. and CouzensG.S.: The Whole Life Prostate Book: Everything that Every Man—at Every Age—Needs to Know About Maintaining Opt

Journal of Urology | October 22, 2012 | Volume: 188 | Issue: 6 | Pages: 2444-2444

10.1016/j.juro.2012.09.066

Definitive therapy for prostate carcinoma: Mayo Clinic results at 15 years after treatment

The British Journal of Radiology | July 15, 2009 | Volume: 67 | Issue: 801 | Pages: 877-889

10.1259/0007-1285-67-801-877 | PMID 7953230

Abstract Data on long-term follow-up for definitive therapy of prostate cancer are limited, especially for radiation therapy. Either surgery or radiation was used in 322 patients for treatment with curative intent, and follow-up was for a minimum of 15 years. Overall survival was nearly identical to that in an age-matched cohort. 5-, 10-, and 15-year recurrence-free survival rates were 77%, 63% and 53%, respectively. Grade and stage were significant prognostic factors for both recurrence and survival. More than 60% of the initial failures were local, and more than 25% of the failures occurred after 10 years. Radiation therapy was used in 137 patients with clinically staged disease. Radical retropubic prostatectomy and perineal prostatectomy were performed in 133 and 44 patients, respectively. In this group, pathological staging was used. Survival rates for surgically treated patients were better than those in the cohort population. In conclusion, overall long-term follow-up demonstrates that definitive treatment does not have an adverse effect on survival from prostate cancer. Local recurrence is a frequent cause of failure. Caution must be used in interpreting any prostate study with less than 10 years of follow-up, because 25% to 50% of the failures occur after that time.
Pharmacoangiographic Evidence of the Presence and Anatomical Dominance of Accessory Pudendal Artery(s)

Journal of Urology | April 19, 2008 | Volume: 179 | Issue: 6 | Pages: 2317-2320

10.1016/j.juro.2008.01.117 | PMID 18423744

Increased Optical Magnification From 2.5× to 4.3× With Technical Modification Lowers the Positive Margin Rate in Open Radical Retropubic Prostatectomy

Journal of Urology | December 5, 2007 | Volume: 179 | Issue: 1 | Pages: 130-135

10.1016/j.juro.2007.08.128 | PMID 17997426

The Anterior Layer of Denonvilliers’ Fascia: A Common Misconception in the Laparoscopic Prostatectomy Literature

Journal of Urology | January 11, 2007 | Volume: 177 | Issue: 2 | Pages: 521-525

10.1016/j.juro.2006.09.028 | PMID 17222624

Salvage Radiotherapy for Isolated Prostate Specific Antigen Increase After Radical Prostatectomy: Evaluation of Prognostic Factors and Creation of a Prognostic Scoring System

Journal of Urology | August 9, 2006 | Volume: 176 | Issue: 3 | Pages: 985-990

10.1016/j.juro.2006.04.083 | PMID 16890677

Re: Saturation Technique Does Not Improve Cancer Detection as an Initial Prostate Biopsy Strategy

Journal of Urology | August 9, 2006 | Volume: 176 | Issue: 3 | Pages: 1252-1253

10.1016/j.juro.2006.04.056 | PMID 16890738

Detectable Prostate Specific Antigen Between 60 and 120 Days Following Radical Prostatectomy for Prostate Cancer: Natural History and Prognostic Significance

Journal of Urology | June 29, 2006 | Volume: 176 | Issue: 2 | Pages: 559-563

10.1016/j.juro.2006.03.086 | PMID 16813889

Increasing Prostate Specific Antigen Following Radical Prostatectomy and Adjuvant Hormonal Therapy: Doubling Time Predicts Survival

Journal of Urology | April 6, 2006 | Volume: 175 | Issue: 5 | Pages: 1684-1690

10.1016/s0022-5347(05)00978-x | PMID 16600730